Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Erivedge (vismodegib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Curis, Roche

Drug class:

Hedgehog cell-signalling pathway inhibitor

Related drugs:

No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	vismodegib Sensitive: A1 - Approval vismodegib Sensitive : A1	vismodegib Sensitive: A1 - Approval vismodegib Sensitive : A1
No biomarker	Medulloblastoma	No biomarker	Medulloblastoma	vismodegib Sensitive: A2 - Guideline vismodegib Sensitive : A2	vismodegib Sensitive: A2 - Guideline vismodegib Sensitive : A2
SMO mutation	Basal Cell Carcinoma	SMO mutation	Basal Cell Carcinoma	vismodegib Resistant: B - Late Trials vismodegib Resistant : B	vismodegib Resistant: B - Late Trials vismodegib Resistant : B
PTCH1 mutation	Medulloblastoma	PTCH1 mutation	Medulloblastoma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
PTCH1 mutation	Melanoma	PTCH1 mutation	Melanoma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
GLI1 overexpression	Basal Cell Carcinoma	GLI1 overexpression	Basal Cell Carcinoma	vismodegib Resistant: C3 – Early Trials vismodegib Resistant : C3	vismodegib Resistant: C3 – Early Trials vismodegib Resistant : C3
PTCH1 mutation	Salivary Gland Cancer	PTCH1 mutation	Salivary Gland Cancer	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
GAS1 underexpression	Basal Cell Carcinoma	GAS1 underexpression	Basal Cell Carcinoma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
PTCH E947T	Soft Tissue Sarcoma	PTCH E947T	Soft Tissue Sarcoma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
SMO P641A	Meningioma	SMO P641A	Meningioma	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3	vismodegib Sensitive: C3 – Early Trials vismodegib Sensitive : C3
PTCH1 1504-1G>T + TMB-H	Basal Cell Carcinoma	PTCH1 1504-1G>T + TMB-H	Basal Cell Carcinoma	nivolumab + vismodegib Sensitive: C4 – Case Studies nivolumab + vismodegib Sensitive : C4	nivolumab + vismodegib Sensitive: C4 – Case Studies nivolumab + vismodegib Sensitive : C4
SMTN P641A	Non Small Cell Lung Cancer	SMTN P641A	Non Small Cell Lung Cancer	vismodegib Sensitive: C4 – Case Studies vismodegib Sensitive : C4	vismodegib Sensitive: C4 – Case Studies vismodegib Sensitive : C4
PTCH1 S616G	Basal Cell Carcinoma	PTCH1 S616G	Basal Cell Carcinoma	vismodegib Sensitive: C4 – Case Studies vismodegib Sensitive : C4	vismodegib Sensitive: C4 – Case Studies vismodegib Sensitive : C4
SMO D473H	Medulloblastoma	SMO D473H	Medulloblastoma	vismodegib Resistant: D – Preclinical vismodegib Resistant : D	vismodegib Resistant: D – Preclinical vismodegib Resistant : D